Drug Resistance in Cancer: An Overview

By Genevieve Housman, Shannon Byler, S. Heerboth, K. Lapinska, Mckenna Longacre, N. Snyder, S. Sarkar. Cancers, 2014

2,239 citations recorded by the source corpus.

Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance. It also describes the epigenetic modifications that can induce drug resistance and considers how such epigenetic factors may contribute to the development of cancer progenitor cells, which are not killed by conventional cancer therapies. Lastly, this review concludes with a discussion on the best treatment options for existing drug resistant cancers, ways to prevent the formation of drug resistant cancers and cancer progenitor cells, and future directions of study.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/14a82ef10b74e5dd4153add7f0f4b90b687d7724

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

K. Guan

Citations in the corpus

Machine learning approaches to drug response prediction: challenges and recent progress (2020, methodology): “Other mechanisms of resistance include modi ﬁ cations to enzymes involved in drug metabolism to either reduce conversion of drugs to active forms or deactivate the compound 58,59 , and more recently, intra-tumor heterogeneity (ITH) 60 .”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “Drug resistance can be classified into two types: 1) innate and 2) acquired [135].”
The Hippo signalling pathway and its implications in human health and diseases (2022, background): “253 – 255 Compelling evidence has shown that the Hippo pathway contributes to the development of chemotherapy resistance.”
EMT and tumor metastasis (2015, background): “As discussed earlier, such changes are involved in forming different degrees of cancer metastasis [2,17,18,25,117,118].”
Molecular targeted therapy: Treating cancer with specificity (2018, background): “Common proteins targeted by therapeutic cancer vaccines include oncoproteins (e.g. RAS, HER2), oncofetal antigens (e.g. carcinoembryonic antigen (CEA), MUC-1), viral proteins (e.g. human papillomavirus (HPV), hepatitis C virus (HCV)), tissue lineage antigens (e.g. prostatic acid phosphatase (PAP), t”